GleamWall
中文EN

VTRS Viatris Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1792044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.3%
TTM net income YoY—
TTM EPS YoY83.1%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-0.0%
Net margin—
FCF margin14.3%
EBITDA margin19.1%

Returns

ROE—
ROA—
ROIC (approx.)-0.0%
Asset turnover0.41x

Leverage & solvency

Liabilities / assets60.5%
Debt / equity0.97x
Current ratio1.55x
Interest coverage-0.01x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$14.30B$14.74B
Cost of revenue$9.29B$9.12B
Gross profit$5.01B$5.62B
R&D expense$965.90M$808.70M
SG&A expense$3.79B$4.10B
Operating income-$2.66B$10.10M
Interest expense$471.30M$550.00M
Pretax income-$3.67B-$623.20M
Income tax-$150.10M$11.00M
Net income-$3.51B-$634.20M
EBITDA$135.20M$2.90B
EPS (basic)-3.00-0.53
EPS (diluted)-3.00-0.53
Dividends declared per share0.480.48
Balance sheet
Cash & equivalents$1.32B$736.10M
Short-term investments$40.70M$38.00M
Receivables$3.03B$3.22B
Inventory$4.00B$3.85B
Current assets$9.79B$9.52B
PP&E, net$2.61B$2.67B
Goodwill$6.75B$9.13B
Intangibles$15.10B$17.07B
Total assets$37.19B$41.50B
Current liabilities$7.09B$5.78B
Short-term debt$1.93B$600,000
Long-term debt$12.48B$14.04B
Total debt$14.41B$14.04B
Total liabilities$22.48B$22.87B
Shareholders' equity$14.71B$18.64B
Net debt$13.09B$13.30B
Cash flow statement
Operating cash flow$2.32B$2.30B
Capital expenditure$378.80M$326.00M
Free cash flow$1.94B$1.98B
Investing cash flow-$427.70M$1.80B
Financing cash flow-$1.29B-$4.33B
Depreciation & amortization$2.80B$2.89B
Stock-based compensation$177.70M$146.10M
Share buybacks$500.50M$250.00M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.